CG Oncology
✦ Quant Ownership Signal how this is computed
- Total institutional ownership fell 2.1 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 116.21% -2.15pp
- Institutions
- 307
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 15 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| Hong Fang Song | Former Independent Director | 0.69% |
| Arthur Kuan | Chairperson & CEO | 0.22% |
| Corleen Roche | Former Chief Financial Officer | 0.00% |
| Vijay Kasturi | Chief Medical Officer | 0.00% |
| Leonard Post | Lead Independent Director | -- |
| James DeTore | Chief Financial Officer | -- |
| Victor Tong | Independent Director | -- |
| Ambaw Bellete | Former Chief Operating Officer | -- |
| Susan Graf | Independent Director | -- |
| ORI Capital | -- | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-14 | Leonard Post | Lead Independent Director | Intent to Sell (Form 144) | -3,000 | $61.84 |
| 2026-10-14 | Leonard Post | Lead Independent Director | Derivative Exercise and Sale | -1,000 | $0.60–62.48 |
| 2026-10-14 | Isabel Kalofonos | Chief Commercial Officer | Other Derivative Acquisition | +92,000 | $61.86 |
| 2026-09-20 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -30,787 | $76.01 |
| 2026-09-16 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -6,532 | $76.50 |
| 2026-09-14 | Leonard Post | Lead Independent Director | Derivative Exercise and Sale | -1,000 | $0.60–72.98 |
| 2026-09-10 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -826 | $75.00 |
| 2026-09-01 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -29,630 | $77.61 |
| 2026-08-30 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -50,000 | $75.51 |
| 2026-08-26 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -5,789 | $79.39 |
| 2026-08-24 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -10,551 | $79.55 |
| 2026-08-23 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -5,762 | $79.52 |
| 2026-08-18 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -100,000 | $79.54 |
| 2026-08-16 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -52,438 | $76.95 |
| 2026-08-13 | Leonard Post | Lead Independent Director | Derivative Exercise and Sale | -1,000 | $0.60–74.54 |
| 2026-08-13 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -19,364 | $75.02 |
| 2026-08-12 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -25,989 | $75.95 |
| 2026-08-11 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -32,137 | $78.62 |
| 2026-08-10 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -50,000 | $76.21 |
| 2026-08-09 | Ambaw Bellete | Former Chief Operating Officer | Intent to Sell (Form 144) | -50,000 | $75.41 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:23 · For reference only, not investment advice and not tailored to your situation.
CG Oncology discussion 0 comments